Guerbet tracks for worst day ever after Raleigh site-induced guidance cut

Guerbet SA

03/12/2025 09:02

** Shares in Guerbet GRBT.PA fall over 25% after it announced a 2025 guidance cut, as FDA inspection issues at its Raleigh site force compliance plan, delay batch releases

** The French pharmaceutical group now sees 2025 revenue down 4-5% (-1% previously), restated EBITDA margin at 10.5%-12% of revenue (12-13% previously)

** Portzamparc double downgrades Guerbet to "sell" from "hold", cuts target price by 41% to 13 euros, citing lack of "visibility for bringing this strategic site back into compliance (potentially 12-18 months)", and its impact on FY 2026

** There are costly resources needed driving exceptional expenses, no timetable, while plant still producing, but US batch-release bottlenecks and site modernisation may freeze production, the broker adds

** Co also sees full-year FCF between -5 million euros  (-$5.82 million) and -15 million euros (seen slightly negative previously)

** Shares are on track for their worst day ever, if losses hold

($1 = 0.8593 euros)

 (Reporting by Olivier Cherfan)

 ((olivier.cherfan@thomsonreuters.com))